CN110392579B - 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 - Google Patents

小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 Download PDF

Info

Publication number
CN110392579B
CN110392579B CN201880016406.5A CN201880016406A CN110392579B CN 110392579 B CN110392579 B CN 110392579B CN 201880016406 A CN201880016406 A CN 201880016406A CN 110392579 B CN110392579 B CN 110392579B
Authority
CN
China
Prior art keywords
myopia
mouse
endoplasmic reticulum
eye
reticulum stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880016406.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110392579A (zh
Inventor
池田真一
姜效炎
坪田一男
栗原俊英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsubota Laboratory Inc
Original Assignee
Tsubota Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Laboratory Inc filed Critical Tsubota Laboratory Inc
Priority to CN202211310272.2A priority Critical patent/CN115645536A/zh
Priority to CN202211310191.2A priority patent/CN115645535B/zh
Publication of CN110392579A publication Critical patent/CN110392579A/zh
Application granted granted Critical
Publication of CN110392579B publication Critical patent/CN110392579B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/02—Breeding vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/06—Lenses; Lens systems ; Methods of designing lenses bifocal; multifocal ; progressive
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
CN201880016406.5A 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 Active CN110392579B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211310272.2A CN115645536A (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
CN202211310191.2A CN115645535B (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-041349 2017-03-06
JP2017041349 2017-03-06
PCT/JP2018/008554 WO2018164113A1 (ja) 2017-03-06 2018-03-06 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202211310272.2A Division CN115645536A (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
CN202211310191.2A Division CN115645535B (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂

Publications (2)

Publication Number Publication Date
CN110392579A CN110392579A (zh) 2019-10-29
CN110392579B true CN110392579B (zh) 2022-11-08

Family

ID=63448602

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211310272.2A Pending CN115645536A (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
CN201880016406.5A Active CN110392579B (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
CN202211310191.2A Active CN115645535B (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202211310272.2A Pending CN115645536A (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211310191.2A Active CN115645535B (zh) 2017-03-06 2018-03-06 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂

Country Status (13)

Country Link
US (2) US12478597B2 (enExample)
EP (1) EP3593817B1 (enExample)
JP (6) JP6637217B2 (enExample)
KR (1) KR102680012B1 (enExample)
CN (3) CN115645536A (enExample)
DK (1) DK3593817T3 (enExample)
ES (1) ES2997337T3 (enExample)
FI (1) FI3593817T3 (enExample)
HR (1) HRP20241734T1 (enExample)
HU (1) HUE069999T2 (enExample)
PL (1) PL3593817T3 (enExample)
PT (1) PT3593817T (enExample)
WO (1) WO2018164113A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6771698B1 (ja) * 2018-12-18 2020-10-21 参天製薬株式会社 ウルソデオキシコール酸を含有する老視の治療または予防剤
CA3123378A1 (en) * 2018-12-18 2020-06-25 Santen Pharmaceutical Co., Ltd. Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
JP7608707B2 (ja) * 2019-02-25 2025-01-07 株式会社坪田ラボ 近視進行抑制剤、機能性食品及び眼科用組成物
US20220105061A1 (en) * 2019-03-08 2022-04-07 The Regents Of The University Of California Compositions and methods for treating respiratory insufficiency
EP4164640A4 (en) * 2020-06-11 2024-07-17 The Trustees of Columbia University in the City of New York METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING MYOPIA WITH BERBERINE, A BERBERIDACENE ALKALOID AND DERIVATIVES THEREOF
KR20230135055A (ko) 2020-12-11 2023-09-22 가부시키가이샤 쓰보타 라보 강막 비박화 치료용 점안제 및 강막 비박화 치료제의스크리닝 방법
TN2023000138A1 (en) * 2020-12-11 2025-01-02 Tsubota Lab Inc Eyedrops for inhibiting myopia progression in children and screening method for inhibitor of myopia progression in children
CN112970666B (zh) * 2021-02-04 2023-02-03 复旦大学附属眼耳鼻喉科医院 一种简便式动物近视诱导装置及制作方法
JP2024069730A (ja) * 2021-03-16 2024-05-22 慶應義塾 網膜変性抑制用組成物
JPWO2023145578A1 (enExample) * 2022-01-25 2023-08-03
WO2023182480A1 (ja) 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
AU2023258808A1 (en) * 2022-04-26 2024-11-07 Tsubota Laboratory, Inc. Method and composition for preventing or treating myopia
CN119998296A (zh) * 2022-08-31 2025-05-13 国立大学法人京都大学 化合物、内质网应激抑制剂、药物、眼科用药、滴眼剂、组合物、化合物的制备方法
CN115777618B (zh) * 2022-11-14 2025-07-08 首都医科大学附属北京同仁医院 一种病理性近视动物模型的构建方法及用途
CN116267712B (zh) * 2023-02-23 2024-08-06 温州医科大学 一种近视眼动物模型的构建方法及其应用
TW202444342A (zh) * 2023-03-24 2024-11-16 日商坪田實驗室股份有限公司 水性組成物
CN116918764B (zh) * 2023-08-28 2025-11-28 河南省儿童医院郑州儿童医院 一种豚鼠近视模型的构建方法
JP7781461B2 (ja) * 2023-10-25 2025-12-08 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
WO2025089394A1 (ja) * 2023-10-25 2025-05-01 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN117797133A (zh) * 2023-12-29 2024-04-02 上海交通大学医学院附属仁济医院 内质网应激抑制剂isrib在制备胎儿宫内生长受限药物中的应用
WO2025182819A1 (ja) * 2024-02-29 2025-09-04 慶應義塾 動物モデルの作製方法
CN120392754B (zh) * 2025-07-02 2025-09-09 深圳市中佳生物医疗科技有限公司 化合物在制备增强造血干细胞代谢活性、治疗异染性脑白质营养不良的产品中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191074C (zh) * 2002-09-18 2005-03-02 王力 熊胆粉滴眼液及其制备方法
CN102917588B (zh) * 2010-03-25 2014-10-08 葛兰素史密斯克莱有限责任公司 化合物
CN103037691B (zh) * 2010-04-28 2016-02-17 香港中文大学 用于预防和治疗高眼压症和青光眼的方法和药物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066561B2 (ja) 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
AU775516B2 (en) 2000-01-18 2004-08-05 Trustees Of The University Of Pennsylvania, The Ocular growth and nicotinic antagonists
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
AU2005284798B2 (en) 2004-09-15 2012-02-02 The President And Fellows Of Harvard College Reducing ER stress in the treatment of obesity and diabetes
US20110130388A1 (en) * 2008-07-24 2011-06-02 Yasushi Ikuno Prophylactic or therapeutic agent for axial myopia
CA2794153C (en) * 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
ES2676393T3 (es) 2011-01-14 2018-07-19 University Of Washington Through Its Center For Commercialization Métodos para diagnosticar y prescribir un protocolo de tratamiento para trastornos relacionados con la longitud ocular
US9724357B2 (en) * 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
GB201217296D0 (en) * 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
WO2015056180A1 (en) * 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
JPWO2015064768A1 (ja) 2013-10-31 2017-03-09 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
WO2016171282A1 (ja) * 2015-04-24 2016-10-27 学校法人慶應義塾 近視予防剤及び近視進行抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191074C (zh) * 2002-09-18 2005-03-02 王力 熊胆粉滴眼液及其制备方法
CN102917588B (zh) * 2010-03-25 2014-10-08 葛兰素史密斯克莱有限责任公司 化合物
CN103037691B (zh) * 2010-04-28 2016-02-17 香港中文大学 用于预防和治疗高眼压症和青光眼的方法和药物

Also Published As

Publication number Publication date
ES2997337T3 (en) 2025-02-17
WO2018164113A1 (ja) 2018-09-13
US12478597B2 (en) 2025-11-25
JP6637217B2 (ja) 2020-01-29
CN115645536A (zh) 2023-01-31
KR102680012B1 (ko) 2024-06-28
JP2024026709A (ja) 2024-02-28
JP2020023574A (ja) 2020-02-13
CN110392579A (zh) 2019-10-29
EP3593817B1 (en) 2024-11-13
JPWO2018164113A1 (ja) 2019-06-27
JP7236753B2 (ja) 2023-03-10
PT3593817T (pt) 2024-12-17
JP6856275B2 (ja) 2021-04-07
KR20190126365A (ko) 2019-11-11
JP2021091731A (ja) 2021-06-17
US20240210736A1 (en) 2024-06-27
US20200150457A1 (en) 2020-05-14
JP7424676B2 (ja) 2024-01-30
HUE069999T2 (hu) 2025-04-28
CN115645535B (zh) 2024-07-09
PL3593817T3 (pl) 2025-03-31
JP2023017050A (ja) 2023-02-02
JP2025013575A (ja) 2025-01-24
EP3593817A4 (en) 2021-04-07
DK3593817T3 (da) 2024-11-25
FI3593817T3 (fi) 2025-02-05
HRP20241734T1 (hr) 2025-02-28
CN115645535A (zh) 2023-01-31
EP3593817A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
CN110392579B (zh) 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂
RU2414904C2 (ru) ЗАЩИТНОЕ СРЕДСТВО ДЛЯ НЕЙРОНА СЕТЧАТКИ, СОДЕРЖАЩЕЕ В КАЧЕСТВЕ АКТИВНОГО КОМПОНЕНТА ПРОИЗВОДНОЕ ПРОСТАГЛАНДИНА F2α
US20240398736A1 (en) Eyedrops for Treating Scleral Thinning and Screening Method for Therapeutic Agent of Scleral Thinning
US20200345805A1 (en) Compositions and methods useable for treatment of dry eye
CN115884782A (zh) 新型干眼症治疗用药物组合物
RU2844958C1 (ru) Способ лечения передних увеитов кошек средней тяжести
JPWO2019093262A1 (ja) 腸内環境制御による近視抑制
김동현 Topical Dopamine Application on Form-Deprivation Myopia in Rabbits
EP4257147A1 (en) Eyedrops for inhibiting myopia progression in children and screening method for inhibitor of myopia progression in children
CN118873659A (zh) 通过靶向过氧化物酶体增殖物激活受体(ppar)信号通路治疗屈光性疾病
El-Nimri Understanding the Link between Myopia and Glaucoma-Clues from Intraocular Pressure and Optic Discs
CN120060460A (zh) 胞外诱捕网在预防和抑制近视发展中的应用
US20100113544A1 (en) Suppressant for cerebral infarction attributed to long-time ischemia
Ramani et al. Management of bilateral cataract by phacoemulsification in a dog
UA62779U (uk) Спосіб лікування первинної відкритокутової глаукоми

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant